Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients

doi:10.3748/wjg.v18.i39.5570

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 39

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3790)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

413

HTML

2940

Figures (1-2)

218

Tables (1-4)

219

Sum=3790

Oct 21, 2012 (publication date) through Nov 28, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Oct 21, 2012; 18(39): 5570-5575
Published online Oct 21, 2012. doi: 10.3748/wjg.v18.i39.5570

Full Size Figure Download Figure

Figure 2 Median quantitative hepatitis B surface antigen levels among patients receiving entecavir therapy. Quantitative hepatitis B surface antigen (HBsAg) levels (qHBsAg) levels in slow-responders in the HBeAg-positive group were significantly higher than those in rapid-responders and the hepatitis B e antigen (HBeAg)-negative group. The median qHBsAg level at year 2 in the slow-responders remained higher than in other groups.

Citation: Orito E, Fujiwara K, Kanie H, Ban T, Yamada T, Hayashi K. Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients. World J Gastroenterol 2012; 18(39): 5570-5575
URL: https://www.wjgnet.com/1007-9327/full/v18/i39/5570.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i39.5570